Eight Advisory carried out the financial buy-side due diligence for PAI Partners, in the context of the acquisition of the SGD Pharma group. In parallel, Eight Advisory Avocats performed the tax buy-side due diligence and the tax structuring.
PAI Partners is a French investment fund that manages and advises funds allocated to LBO transactions (representing an amount of €7 billion) and manages a portfolio of investments with a total capital invested of over €14 billion.
SGD Pharma is a global leader in glass pharmaceutical packaging. SGD Pharma produces over 8 million vials and bottles per day in its five manufacturing plants in Europe and Asia.
Following the acquisition by PAI Partners, SGD is valued at between €800 and €850 million.
The Eight Advisory team was composed of Christian Berling and Adrien de La Bouillerie.
The Eight Advisory Tax team was composed of Guillaume Rembry, Kévin Peau, Guillaume Exerjean, Priscille Baizeau and Imane Sellam.